Nanobac Introduces New Improved ELISA Kits for Detection of Calcifying
Nano-Particles, also known as Nanobacteria
10/26/2005 8:00:00 AM EST
Nanobac Life Sciences, Inc. (OTCBB: NNBP) ("Nanobac" or "the Company")
announced today the introduction of two new versions of its
NANOCAPTURE(TM) and NANO-SERO(TM) ELISA test kits for the detection of
Calcifying Nano-Particles (CNPs), also known as nanobacteria, in serum
or plasma. The new kits offer improved sensitivity, lower background
and improved stability over the previous versions. Nanobac has added
new standards to improve precision at the low end and freeze dried the
critical components for improved stability.
"Our demand for CNP diagnostic products is increasing as CNP's or
nanobacteria are implicated in more and more chronic diseases," stated
Grant Carlson, Nanobac's President and Chief Operating Officer.
"Nanobac has worked hard to develop robust, sensitive and reproducible
ELISA test kits for the CNP/nanobacteria research community. These kits
are CE marked and ready for immediate shipment throughout the European
Union. In the United States the kits will be sold For Research Use Only
(RUO)."
The NANOCAPTURE ELISA is a two-site immunoenzymatic assay for the
quantitative measurement of CNP/nanobacterial antigen in serum or
plasma. The NANO-SERO ELISA is also a two site immunoenzymatic assay
for the quantitative measurement of anti-CNP antibodies in serum or
plasma. Nanobac will feature the NANOCAPTURE and NANO-SERO ELISA test
kits at the world's #1 medical trade show, MEDICA, in Dusseldorf,
Germany, November 16-19, 2005. Last year the show attracted 136,000
visitors from around the world. Nanobac intends to meet with potential
customers and establish its global network of in vitro diagnostic
distributors.
About Nanobac Life Sciences
Nanobac Life Sciences, Inc. is a broad-based life science company that
discovers, develops, manufactures, and markets a range of products and
services to improve people's health through the detection and treatment
of Calcifying Nano-Particles, otherwise known as "nanobacteria". The
Company's pioneering research is establishing the pathogenic role of
nanobacteria in soft tissue calcification, particularly in coronary
artery heart disease, prostatitis and vascular disease.
Nanobac manufactures and markets In Vitro Diagnostic (IVD) kits and
reagents for the detection of Calcifying Nano-Particles. IVD products
include the NANOCAPTURE(TM) and NANO-SERO(TM) ELISA assays and the
Nano-Vision(TM) line of antibodies and reagents. Nanobac's
BioAnalytical Services works with biopharmaceutical partners to develop
and apply methods for avoiding, detecting, and inactivating or
eliminating CNPs from raw materials. Nanobac's Drug Discovery and
Development efforts are focused on developing new and existing
compounds that effectively inhibit, destroy or neutralize CNPs. The
Company also markets Dietary Supplements through its subsidiary,
Nanobac Sciences, LLC.
Nanobac Life Sciences, Inc. is headquartered in Tampa, Florida. For
more information, please visit our website at: http://www.nanobac.com.
Investors are cautioned that certain statements contained in this
document as well as some statements in periodic press releases and some
oral statements of Nanobac Life Sciences, Inc. officials are
"Forward-Looking Statements" within the meaning of the Private
Securities Litigation Reform Act of 1995 (the "Act). Forward-Looking
statements include statements which are predictive in nature, which
depend upon or refer to future events or conditions, which include
words such as "believes," "anticipates," "intends," "plans," "expects,"
and similar expressions. In addition, any statements concerning future
financial performance (including future revenues, earnings or growth
rates), ongoing business strategies or prospects, and possible future
Nanobac Life Sciences, Inc. actions, which may be provided by
management, are also forward-looking statements as defined by the Act.
Forward-Looking statements involve known and unknown risks,
uncertainties, and other factors which may cause the actual results,
performance or achievements of the Company to materially differ from
any future results, performance or achievements expressed or implied by
such forward-looking statements and to vary significantly from
reporting period to reporting period. Although management believes that
the assumptions will, in fact, prove to be correct or that actual
future results will not be different from the expectations expressed in
this report. These statements are not guarantees of future performance
and Nanobac Life Sciences, Inc. has no specific intention to update
these statements.
CONTACT:
Nanobac Life Sciences, Inc. John Stanton, CEO or Grant Carlson,
President/COO
Telephone: (813) 264-2241
Website: www.nanobaclabs.com